ASSESSMENT OF INTERACTION OF COCAINE AND QUETIAPINE (SEROQUEL)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Study Objectives: This is a human laboratory clinical pharmacology study to assess the safety of intravenous cocaine in subjects taking quetiapine at 3 dosage levels. The purpose is to provide preliminary subjective, safety, and tolerability data to inform a decision on whether clinical trials of quetiapine in cocaine dependence should be conducted. Primary: the primary objective is to determine whether there are significant interactions between quetiapine administered concurrently with IV cocaine infusions of 20 mg and 40 mg by measuring subjective, laboratory, and physiologic responses. Secondary: 1. To evaluate whether the administration of quetiapine alters the pharmacokinetics of cocaine or its major metabolite, benzoylecgonine (BE). 2. To evaluate whether treatment with quetiapine alters the effects of cocaine on craving, as measured by subjective rating scales that assess abuse liability, for the purpose of determining whether there is a signal for potential efficacy in cocaine dependence. 3. To assess the effect of quetiapine on mood and personality using standard assessment scales.